Inactivation of a pathogen in a sample by a treatment with formalin and UV light
View Patent ↗The present invention relates to a method for inactivating virus in a sample by treating a virus containing sample with an effective concentration of formalin and by treating the sample with an effective dose of UV light in a flow-through apparatus.
1. A method for inactivating an enveloped virus contained in a sample for producing a vaccine, comprising the steps of
(i) treating the sample with an effective concentration of formalin, and
(ii) subjecting the sample to an effective dose of UV light in a flow-through apparatus,
wherein step (i) is performed prior to step (ii) or vice versa, and
wherein the enveloped virus is wholly inactivated, thereby being suitable for use in producing the vaccine.
2. The method of claim 1 , wherein the virus titre reduction due to the inactivation of the virus in the sample is at least about 1×10 5 .
3. The method of claim 1 , wherein the virus titre reduction due to the inactivation of the virus in the sample is at least about 1×10 7 .
4. The method of claim 1 , wherein the virus titre reduction due to the inactivation of the virus in the sample is at least about 1×10 10 .
5. The method of claim 1 , wherein the virus titre reduction due to the inactivation of the virus in the sample is at least about 1×10 14 .
6. The method of claim 1 , wherein the step of treating the sample with an effective concentration of formalin is carried out for about 12 to about 96 hours.
7. The method of claim 1 , wherein the effective concentration of formalin is about 0.01 to about 0.1%.
8. The method of claim 1 , wherein the UV light is UVC with a wavelength of about 100 to about 280 nm.
9. The method of claim 1 , wherein the dose of UV light is about 5 to about 200 mJ/cm2.
10. The method of claim 1 , wherein the contact time of the sample with the UV light is about 1 to about 20 seconds.
11. The method of claim 1 , wherein the flow rate in the flow-through apparatus is from about 50 liters per hour to about 1000 liters per hour.
12. The method of claim 1 , wherein the flow-through apparatus contains a thin layer chamber.
13. The method of claim 12 , wherein the thin layer of the thin layer chamber has a thickness of about 1 mm.
14. The method of claim 1 , wherein the step of subjecting the sample to an effective dose of UV light in a flow-through apparatus is repeated for about 2 to about 10 times.
15. The method of claim 1 , wherein the sample is selected from the group consisting of biological fluids, or solutions originating from a cell culture process.
16. The method of claim 1 further comprising the step of subjecting the sample to a purification step to remove residual formalin in the sample.
17. The method of claim 1 further comprising purifying the inactivated virus in the sample to pharmaceutical purity, and formulating the purified inactivated virus into a pharmaceutical composition for use as a vaccine.
18. The method of claim 1 , further comprising a test subsequent to steps (i) and (ii) to determine the residual infectivity of the inactivated virus, the test comprising the steps of
a) inoculating a mammalian cell culture with the inactivated enveloped virus
b) incubating the cell culture,
c) harvesting the cell culture and inoculating a second mammalian cell culture with the harvest,
d) incubating the second mammalian cell culture,
e) harvesting the second mammalian cell culture and testing the harvest for hemagglutinin activity,
wherein the results from the test indicate that the enveloped virus is wholly inactivated, thereby being suitable for use in producing the vaccine.
19. The method of claim 18 , wherein the mammalian cell culture is a VERO cell culture.
20. The method of claim 18 , wherein the cell culture is incubated for about 7 days in step b) or d).